Italy: Growing Private Sector, Limited Public Funding In Italy: Wegovy and Saxenda are both approved for obesity treatment Most people get these medicines through private doctors Public healthcare may cover these medicines in exceptional cases, but only for people with very severe obesity and serious health problems National rules are slowly changing, but public coverage is still limited and not consistent across the country Private costs in Italy: About 250 to 350 per month for Wegovy About 200 to 300 per month for Saxenda Who prescribes GLP-1s in Italy
The most-used screening test is a mammogram, which is an X-ray of the breast
This ensures you have the correct, laboratory-grade diluent matched to your peptide supply from a single verified source dispatched from UK stock
The responsible path is to follow the data closely, give patients honest assessments, and be ready when the evidence catches up to the promise
Available in 10mg and 20mg
This revenue growth is a testament to the market potential of Eli Lillys weight loss treatments and the companys ability to scale its operations effectively